Premium
Multiple milia formation induced by dovitinib
Author(s) -
Shin Dongyun,
Seo Jimyung,
Kim Soo Min,
Kim Do Young
Publication year - 2015
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12799
Subject(s) - rash , platelet derived growth factor receptor , fibroblast growth factor , tyrosine kinase inhibitor , cancer research , tyrosine kinase , medicine , receptor tyrosine kinase , vascular endothelial growth factor , growth factor , receptor , vegf receptors , dermatology , cancer
Dovitinib is a novel multi‐target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor‐1–3, platelet‐derived growth factor receptor‐β, Fms‐like tyrosine kinase 3, c‐Kit and fibroblast growth factor receptor‐1–3. This compound is currently being assessed clinically for treatment of various malignancies. In phase I and II clinical trials of dovitinib treatment for renal cell carcinoma, 20% of patients experienced cutaneous adverse events, although the specific type of skin rash was not documented. Here, we report two cases of multiple milia formation induced by dovitinib. We believe our cases are the first report mainly showing non‐inflammatory cystic structure.